Artificial Hydrogenases Based on Cobaloximes and Heme Oxygenase.

The insertion of cobaloxime catalysts in the heme-binding pocket of heme oxygenase (HO) yields artificial hydrogenases active for H evolution in neutral aqueous solutions. These novel biohybrids have been purified and characterized by using UV/visible and EPR spectroscopy. These analyses revealed the presence of two distinct binding conformations, thereby providing the cobaloxime with hydrophobic and hydrophilic environments, respectively.

Cobaloxime-based artificial hydrogenases.

Cobaloximes are popular H2 evolution molecular catalysts but have so far mainly been studied in nonaqueous conditions. We show here that they are also valuable for the design of artificial hydrogenases for application in neutral aqueous solutions and report on the preparation of two well-defined biohybrid species via the binding of two cobaloxime moieties, {Co(dmgH)2} and {Co(dmgBF2)2} (dmgH2 = dimethylglyoxime), to apo Sperm-whale myoglobin (SwMb). All spectroscopic data confirm that the cobaloxime moieties are inserted within the binding pocket of the SwMb protein and are coordinated to a histidine residue in the axial position of the cobalt complex, resulting in thermodynamically stable complexes.

[Clinical course and the effectiveness of conservative treatment of prolactin-secreting pituitary adenoma].

Forty-eight women with prolactin-secreting adenomas of the hypophysis and 22 patients with suspected microadenomas, aged 16 to 38, were examined. The highest blood prolactin levels and the most manifest symptoms were revealed in the patients with x-ray evidence of hypophyseal macroadenoma. Prolactin levels were lower, though still elevated, in the cases with small adenomas.

[Dynamics of the corticotropin, cortisol and prolactin content of the blood plasma of women with Itsenko-Cushing disease administered luliberin].

The paper is concerned with the results of a study of the level of plasma ACTH, cortisol and prolactin before and after i. v. injection of LHRH to 20 patients with Itsenko-Cushing disease and to 5 healthy persons.